Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221571 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
A Phase 1 study of Hodgkin Lymphoma, sponsored by Affimed.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT01221571 is a Phase 1 study of Hodgkin Lymphoma that has completed, run by Affimed. The registered enrollment target is 28 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01221571, a Phase 1 study of Hodgkin Lymphoma, has completed, sponsored by Affimed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.
Conditions Studied
Interventions
- DRUG AFM 13
Study Locations (3)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Köln
- University Hosptial Cologne - Cologne
Other
- University Hospital Würzburg - Würzburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221571
The ClinicalTrials.gov registry entry for NCT01221571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AFM 13 is the first listed.
NCT01221571 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Texas, Köln, Other.
Frequently Asked Questions
What is clinical trial NCT01221571 about?
NCT01221571 is a clinical study titled "A Study to Assess AFM13 in Patients With Hodgkin Lymphoma". The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.
What is the current status of trial NCT01221571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-10. Estimated completion is 2013-06.
What conditions does trial NCT01221571 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT01221571?
The interventions under investigation include: AFM 13 (DRUG).
Who is sponsoring clinical trial NCT01221571?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01221571 being conducted?
This trial has 3 study locations across Texas, Köln. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.